A Multiplex SNaPshot Assay As a Rapid Method for Detecting KRAS and BRAF Mutations in Advanced Colorectal Cancers

Overview

Journal J Mol Diagn

Publisher Elsevier

Specialties Molecular Biology
Pathology

Date 2011 Jul 12

PMID 21742054

Citations 17

Authors

Sandrine Magnin

Erika Viel

Alice Baraquin

Severine Valmary-Degano

Bernadette Kantelip

Jean-Luc Pretet

Christiane Mougin

Marthe Bigand

Benoit Girardo

Christophe Borg

Christophe Ferrand

Affiliations

Soon will be listed here.

Abstract

The analysis of KRAS mutations has become a prerequisite for anti-epidermal growth factor receptor therapy in patients with metastatic colorectal cancers. KRAS mutations are associated with resistance to treatment by monoclonal antibodies such as cetuximab and panitumumab and thus are correlated with a shorter progression-free survival. BRAF mutations also may play a role in treatment decisions. The widespread use of these targeted therapies has generated the need to develop cost-effective methods for routine KRAS and BRAF analysis. The aim of this study was to compare a multiplex SNaPshot assay with DNA sequencing and high-resolution melting analysis for identifying KRAS codons 12 and 13 and BRAF codon 600 mutations. Thus 110 routinely formalin-fixed and paraffin-embedded tissue blocks were tested by each method. The SNaPshot analysis detected KRAS and BRAF codon 600 mutations in, respectively, 34.5% (n = 38) and 10% (n = 11) of these tissue blocks. These results were confirmed by direct DNA sequencing and by high-resolution melting analysis. The costs and time constraints of each detection method were compared at the same time. In conclusion, our newly designed multiplex SNaPshot assay is a fast, inexpensive, sensitive, and robust technique for molecular diagnostic practices and patient selection.

Citing Articles

Evaluation of SNaPshot and Sanger sequencing for the detection of and mutations in a sample of Venezuelan patients with colorectal cancer.

Rodriguez-Carrascal D, Puche R, Acosta M, Ramirez C Ecancermedicalscience. 2025; 18():1797.

PMID: 39816392 PMC: 11735137. DOI: 10.3332/ecancer.2024.1797.

An innovative single-base extension method for synchronous detection of point mutations and MSI status in colorectal cancer.

Liang L, Li X, Nong L, Cai W, Zhang J, Liu P Cancer Med. 2022; 12(7):8367-8377.

PMID: 36583506 PMC: 10134345. DOI: 10.1002/cam4.5557.

The Sensitivity and Specificity of Novel Primers for Detection of BRAFV600E Mutation.

Tayeb B, Pringle H Asian Pac J Cancer Prev. 2020; 21(11):3191-3198.

PMID: 33247675 PMC: 8033103. DOI: 10.31557/APJCP.2020.21.11.3191.

An enzymatic on/off switch-mediated assay for KRAS hotspot point mutation detection of circulating tumor DNA.

Wang Q, Zhou C, Yin Y, Xiao L, Wang Y, Li K J Clin Lab Anal. 2020; 34(8):e23305.

PMID: 32207862 PMC: 7439329. DOI: 10.1002/jcla.23305.

Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC).

Pang S, Awi N, Armon S, Lim W, Low J, Peh K Diagnostics (Basel). 2019; 10(1).

PMID: 31877940 PMC: 7168209. DOI: 10.3390/diagnostics10010009.

References

Weichert W, Schewe C, Lehmann A, Sers C, Denkert C, Budczies J . KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn. 2009; 12(1):35-42. PMC: 2797716. DOI: 10.2353/jmoldx.2010.090079. View

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P . Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26(35):5705-12. DOI: 10.1200/JCO.2008.18.0786. View

van Dongen J, Langerak A, Bruggemann M, Evans P, Hummel M, Lavender F . Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17(12):2257-317. DOI: 10.1038/sj.leu.2403202. View

Do H, Solomon B, Mitchell P, Fox S, Dobrovic A . Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes. 2008; 1:14. PMC: 2442881. DOI: 10.1186/1756-0500-1-14. View

Lurkin I, Stoehr R, Hurst C, VAN Tilborg A, Knowles M, Hartmann A . Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One. 2010; 5(1):e8802. PMC: 2809099. DOI: 10.1371/journal.pone.0008802. View

Amicarelli G, Shehi E, Makrigiorgos G, Adlerstein D . FLAG assay as a novel method for real-time signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations. Nucleic Acids Res. 2007; 35(19):e131. PMC: 2095824. DOI: 10.1093/nar/gkm809. View

Allegra C, Jessup J, Somerfield M, Hamilton S, Hammond E, Hayes D . American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009; 27(12):2091-6. DOI: 10.1200/JCO.2009.21.9170. View

Ma E, Wong C, Law F, Chan W, Siu D . Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. J Clin Pathol. 2009; 62(10):886-91. DOI: 10.1136/jcp.2008.063677. View

Murphy J, Ryan D . American Society of Clinical Oncology 2010 colorectal update. Expert Rev Anticancer Ther. 2010; 10(9):1371-3. DOI: 10.1586/era.10.123. View

10.

Richman S, Seymour M, Chambers P, Elliott F, Daly C, Meade A . KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009; 27(35):5931-7. DOI: 10.1200/JCO.2009.22.4295. View

11.

Chang Y, Yeh K, Chang T, Chai C, Lu H, Hsu N . Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer. 2009; 9:179. PMC: 2702390. DOI: 10.1186/1471-2407-9-179. View

12.

Shaw R, Cantley L . Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006; 441(7092):424-30. DOI: 10.1038/nature04869. View

13.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G . Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11(8):753-62. DOI: 10.1016/S1470-2045(10)70130-3. View

14.

Karapetis C, Khambata-Ford S, Jonker D, OCallaghan C, Tu D, Tebbutt N . K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359(17):1757-65. DOI: 10.1056/NEJMoa0804385. View

15.

Dufort S, Richard M, De Fraipont F . Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem. 2009; 391(2):166-8. DOI: 10.1016/j.ab.2009.05.027. View

16.

Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S . PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009; 69(5):1851-7. DOI: 10.1158/0008-5472.CAN-08-2466. View

17.

Gonzalez-Cadavid N, Zhou D, Battifora H, Bar-Eli M, Cline M . Direct sequencing analysis of exon 1 of the c-K-ras gene shows a low frequency of mutations in human pancreatic adenocarcinomas. Oncogene. 1989; 4(9):1137-40. View

18.

Amado R, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman D . Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(10):1626-34. DOI: 10.1200/JCO.2007.14.7116. View

19.

Oikonomou E, Pintzas A . Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies. Anticancer Res. 2006; 26(2A):1077-84. View

20.

Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais M . Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007; 96(8):1166-9. PMC: 2360149. DOI: 10.1038/sj.bjc.6603685. View